ArticleRMD open2026
Cognitive impairment risk in patients with rheumatoid arthritis: a population-based cohort study.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the incidence rate and incident cognitive impairment risk in patients with rheumatoid arthritis (RA) compared with matched controls.
methodsThis population-based matched cohort study enrolled patients newly diagnosed with RA (n=26 437) between 2011 and 2014 and 1:1 age-, sex- and index-year-matched controls (n=26 437) from a Korean nationwide claims database. Follow-up spanned the index date to the earliest occurrence of incident cognitive impairment or December 2022. Cognitive impairment was defined using the International Classification of Diseases, 10th Revision, codes (F00-F03, F31.82, F06.7, G30 and G31.00). Incidence rates were calculated as events per 1000 person-years. Multivariable stratified competing risks regression analyses estimated adjusted subdistribution HRs (SHRs) with 95% CIs for incident cognitive impairment, treating death as a competing risk.
resultsDuring the mean respective follow-up of 9.410±2.271 and 9.508±2.217 years, 2952 (11.17%) and 2388 (9.03%) patients with RA and controls developed incident cognitive impairment, respectively. The cognitive impairment incidence rates in patients with RA and controls were 11.493 (95% CI 7.648 to 15.338) and 9.219 (95% CI 5.386 to 13.052) per 1000 person-years, respectively. Compared with the control individuals, patients with RA had a significantly higher risk of developing cognitive impairment (adjusted SHR, 1.222 (95% CI 1.171 to 1.275)).
conclusionsThese findings suggest that cognitive impairment may represent an important comorbidity in patients with RA that merits clinical awareness and longitudinal monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.